Abiopharma

🔍 Hazelbaker Jill (Executive)

Company: Uber Technologies, Inc (UBER)

Report Date: 2026-08-16

Detailed Transactions and Holdings:

• Acquired 351 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 173,513.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,416 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 174,929.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,888 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 176,817.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,465 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 178,282.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,493 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 179,775.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,546 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 182,321.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 176 shares of Common Stock at $75.95 per share (Direct)
  Date: 2026-08-16 | Code: F | equity_swap_involved: false | shares_owned_after: 182,145.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 710 shares of Common Stock at $75.95 per share (Direct)
  Date: 2026-08-16 | Code: F | equity_swap_involved: false | shares_owned_after: 181,435.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 946 shares of Common Stock at $75.95 per share (Direct)
  Date: 2026-08-16 | Code: F | equity_swap_involved: false | shares_owned_after: 180,489.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 734 shares of Common Stock at $75.95 per share (Direct)
  Date: 2026-08-16 | Code: F | equity_swap_involved: false | shares_owned_after: 179,755.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 748 shares of Common Stock at $75.95 per share (Direct)
  Date: 2026-08-16 | Code: F | equity_swap_involved: false | shares_owned_after: 179,007.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,312 shares of Common Stock at $75.95 per share (Direct)
  Date: 2026-08-16 | Code: F | equity_swap_involved: false | shares_owned_after: 177,695.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: H | nature_of_ownership: Trust | shares_owned_after: 11,974.00 | Footnotes: F3
• Sold 351 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 15,802.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Sold 1,416 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 60,891.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5
• Sold 1,888 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 81,188.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6
• Sold 1,465 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 45,417.00 | transaction_form_type: 4 | Footnotes: F1, F7, F7
• Sold 1,493 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 28,371.00 | transaction_form_type: 4 | Footnotes: F1, F8, F8
• Sold 2,546 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-16 | Code: M | equity_swap_involved: false | shares_owned_after: 17,826.00 | transaction_form_type: 4 | Footnotes: F1, F9, F9

Footnotes:

• F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
• F2: Shares withheld to satisfy tax liability upon vesting of RSUs on August 16, 2026.
• F3: Shares are held by the Franks 2021 Irrevocable Trust of which the beneficiaries are members of Ms. Hazelbaker's immediate family.
• F4: The reporting person was granted 16,855 RSUs on May 11, 2026. The vesting schedule is as follows: 1/48 of the total RSUs vested on June 16, 2026 and 1/48 of the total RSUs vest each month thereafter. Upon vesting, the RSUs become payable in cash or common stock on a one-for-one basis at the election of the Issuer.
• F5: The reporting person was granted 67,971 RSUs on March 18, 2026. The vesting schedule is as follows: 1/48 of the total RSUs vested on April 16, 2026, and 1/48 of the total RSUs vest each month thereafter. Upon vesting, the RSUs become payable in cash or common stock on a one-for-one basis at the election of the Issuer.
• F6: The reporting person was granted 90,628 RSUs on March 2, 2026. The vesting schedule is as follows: 1/48 of the total RSUs vested on April 16, 2026, and 1/48 of the total RSUs vest each month thereafter. Upon vesting, the RSUs become payable in cash or common stock on a one-for-one basis at the election of the Issuer.
• F7: The reporting person was granted 70,323 RSUs on March 3, 2025. The vesting schedule is as follows: 1/48 of the total RSUs vested on April 16, 2025 and 1/48 of the total RSUs vest each month thereafter. Upon vesting, the RSUs become payable in cash or common stock on a one-for-one basis at the election of the Issuer.
• F8: The reporting person was granted 71,674 RSUs on March 1, 2024. The vesting schedule is as follows: 1/48 of the total RSUs vested on April 16, 2024 and 1/48 of the total RSUs vest each month thereafter. Upon vesting, the RSUs become payable in cash or common stock on a one-for-one basis at the election of the Issuer.
• F9: The reporting person was granted 122,235 RSUs on March 1, 2023. The vesting schedule is as follows: 1/48 of the total RSUs vested on April 16, 2023 and 1/48 of the total RSUs vest each month thereafter. Upon vesting, the RSUs become payable in cash or common stock on a one-for-one basis at the election of the Issuer.
• REMARKS: President and Chief Corporate Affairs Officer